ONCOassist

ONCOassist A revolutionary app designed by oncology professionals for oncology professionals. The go-to app for all oncology professionals.

It gives them comfort where they can access relevant, up to date tools and content at their fingertips. It is the only mobile-first platform that saves time and improves the quality of patient care for frustrated and under pressure oncology HCPs. With the advent of genomic sequencing, combined with an aging population, and new therapies. The decision-making process for oncology HCP's is becoming increasingly complex. Unfortunately, they have no easy access to the tools and information they need to make an informed decision quickly. This means they use multiple different software and tools to aid their decisions, many of which are not safe and validated. This wastes time & reduces the quality of patient care. We focus on making ONCOassist easily accessible to all oncology HCP’s by being available across multiple devices(iOS, Android, and Desktop) and ensuring safety through CE and FDA compliance. Such is the need for ONCOassist our community of users are actively engaging with us to help define our future tools based on their burning needs. ONCOassist is improving the delivery of cancer care globally and helping us to reach our goal of leveling the standard of care worldwide.

🚨Latest Approval Alert!✅ Imfinzi (durvalumab) becomes the first perioperative immunotherapy approved in the US for early...
26/11/2025

🚨Latest Approval Alert!

✅ Imfinzi (durvalumab) becomes the first perioperative immunotherapy approved in the US for early gastric & gastroesophageal cancers.

Phase III MATTERHORN data show strong outcomes:
🔹 29% lower risk of progression, recurrence or reduced overall survival.
🔹 22% lower risk of reduced overall survival vs. standard chemo

🔗 Read more: bit.ly/ONCOnews26N-1

🚨New in !🔔 PharmaEssentia USA Corporation, announces that positive results from its pivotal Phase 3 SURPASS-ET clinical...
25/11/2025

🚨New in !

🔔 PharmaEssentia USA Corporation, announces that positive results from its pivotal Phase 3 SURPASS-ET clinical trial have been published in The Lancet Haematology.

➡️ The SURPASS-ET compared ropeginterferon alfa-2b vs anagrelide in hydroxyurea-resistant/intolerant Essential Thrombocythemia (ET) with leukocytosis.

📌 FDA submission for BESREMi® (Ropeginterferon alfa-2b) label expansion expected before the end of 2025.

🔗 Read more: bit.ly/ONCOnews25N-2

🚨Latest Approval Alert!🔔 The European Commission approves expanded use of Breyanzi® (lisocabtagene maraleucel; liso-cel)...
25/11/2025

🚨Latest Approval Alert!

🔔 The European Commission approves expanded use of Breyanzi® (lisocabtagene maraleucel; liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma (MCL).

🧬 In the TRANSCEND MCL trial, 82.7% of patients responded, with 71.6% achieving a complete response, and over 50% maintaining response at 24 months.

🔗 Read more: bit.ly/ONCOnews25N-1

🚨FDA Approval Update!🔔 The FDA has approved pembrolizumab (Keytruda, Merck) or (Keytruda Qlex, Merck) in combination wit...
24/11/2025

🚨FDA Approval Update!

🔔 The FDA has approved pembrolizumab (Keytruda, Merck) or (Keytruda Qlex, Merck) in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as a neoadjuvant + adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin.

🎯 The major efficacy outcome measure was event-free survival (EFS) assessed by blinded independent central review.

🔗 Read more: bit.ly/ONCOnews24N-1

🚨FDA Approval Alert!🔔 FDA grants accelerated approval to Sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.) fo...
21/11/2025

🚨FDA Approval Alert!

🔔 FDA grants accelerated approval to Sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy.

➡️ FDA also clears the Oncomine Dx Target Test as a companion diagnostic to identify eligible patients.

🔗 Read more: bit.ly/ONCOnews21N-4

🚨FDA Approval Alert!🔔 The FDA has granted full approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen ...
21/11/2025

🚨FDA Approval Alert!

🔔 The FDA has granted full approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) in combination with VCd for newly diagnosed light chain (AL) amyloidosis, converting its 2021 accelerated approval to traditional approval.

✅ This decision is supported by results from the ANDROMEDA Phase 3 trial.

🔗 Read more: bit.ly/ONCOnews21N-3

🚨FDA Approval Alert!📢 FDA approves selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromato...
21/11/2025

🚨FDA Approval Alert!

📢 FDA approves selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) experiencing symptomatic, inoperable plexiform neurofibromas.

🔹FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.

🔗 Read more: bit.ly/ONCOnews21N-2

🚨European Union Approval Alert!✅ EU approves Libtayo® (cemiplimab) as the first immunotherapy for adjuvant treatment of ...
21/11/2025

🚨European Union Approval Alert!

✅ EU approves Libtayo® (cemiplimab) as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.

📉 Phase 3 C-POST trial: Significant improvement in disease-free survival with a 68% reduction in recurrence.

🔗 Read more: bit.ly/ONCOnews21N-1

🚨FDA Approval Alert!✅ FDA grants full approval to Amgen's IMDELLTRA® (tarlatamab-dlle) in extensive stage small cell lun...
20/11/2025

🚨FDA Approval Alert!

✅ FDA grants full approval to Amgen's IMDELLTRA® (tarlatamab-dlle) in extensive stage small cell lung cancer (ES-SCLC).

🎯 Phase 3 DeLLphi-304 shows 40% reduction in risk of death vs chemo.

🔗 Read more: bit.ly/ONCOnews20N3

🚨Latest in Oncology!🆕 EU approves Roche’s Lunsumio® (mosunetuzumab) subcutaneous (SC) for relapsed/refractory follicular...
20/11/2025

🚨Latest in Oncology!

🆕 EU approves Roche’s Lunsumio® (mosunetuzumab) subcutaneous (SC) for relapsed/refractory follicular lymphoma — offering deep, durable responses even in later-line disease.

⏱️ New subcutaneous option cuts administration time to ~1 minute, supporting faster care and greater treatment flexibility for patients.

🔗 Read more: bit.ly/ONCOnews20N-2

Address

3rd Floor, 41/42, High Street
Killarney
V93T8K7

Website

Alerts

Be the first to know and let us send you an email when ONCOassist posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ONCOassist:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category